A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products.
Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
Recently, the 2025 Deloitte China Technology Fast Program Award Ceremony was successfully held in Wuxi, China. After a three-month selection process, Dermavon, the skin health business company of CMS, was included in the list of “Deloitte China LSHC Rising Star” by virtue of its leading innovative product layout in the skin health field, as well as its promising growth and development potential. The theme of this year’s “Technology Fast Program” selection is “Boundless Innovation, Resilient Growth”. Through the review by the Professional Committee, enterprise presentation and scoring, and other processes, the selection comprehensively evaluates enterprise valuation, technological innovation, market prospects, industry ranking, etc., and selects excellent enterprises with both innovation capabilities and growth potential, so as to encourage enterprises to break through technological boundaries and promote the continuous construction of the innovation ecosystem. Being selected into this list is a full recognition of Dermavon’s leading industry position, comprehensive and differentiated innovative product portfolio, […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.